Welcome to our dedicated page for Akari Therapeutics Plc SEC filings (Ticker: AKTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Akari Therapeutics plc filings document the regulatory record of an England and Wales biotechnology issuer whose ordinary shares trade on Nasdaq only in connection with American Depositary Shares. The company’s SEC disclosures cover S-1 registration statements, 8-K material-event reports, proxy materials, and shareholder voting results tied to its ADS and ordinary-share structure.
Akari’s filings describe securities offerings, private placements, warrants, note exchanges, ADS ratio matters, Nasdaq listing-rule approvals, and amendments affecting share capital. Proxy and meeting materials also document U.K. public-company governance, quorum and voting mechanics, security-holder rights, and approvals related to the company’s capital structure.
Akari Therapeutics plc (AKTX) insider Form 4: Gaslightwala Abizer, listed as both CEO and a director, reported multiple open-market purchases of the company’s American Depositary Shares in August 2025. Each American Depositary Share (ADS) represents 2,000 ordinary shares. On 08/21/2025 he acquired 10,000 ADS at a weighted average price of $0.94 increasing his holdings to 287,574 ADS. On 08/22/2025 he acquired 8,000 ADS at $0.93 (holdings: 295,574 ADS), and on 08/25/2025 he acquired 3,000 ADS at $0.90 (holdings: 298,574 ADS). The filing is signed by an attorney-in-fact on 08/29/2025.
Akari Therapeutics plc disclosed that its Chairman, Dr. Hoyoung Huh, purchased a Note with a $1,250,000 principal amount for a purchase price of $1,000,000. The purchase was satisfied with $162,567 in cash and by cancelling $837,433 of outstanding principal and accrued interest under a senior secured promissory note previously issued to him by the companys subsidiary, Peak Bio Inc. The company and Dr. Huh executed a Loan Cancellation and Exchange Agreement on August 7, 2025, to effect the cancellation; the full agreement is filed as Exhibit 10.1 to the Form 8-K.
Akari Therapeutics, Plc filed a current report to let investors know it has released an updated corporate investor presentation. The company states that this updated presentation, attached as Exhibit 99.1, will be used by its representatives in various meetings with investors and other stakeholders from time to time.
The information in this presentation is furnished under a Regulation FD disclosure, meaning it is intended to provide broad, fair disclosure but is not treated as filed for liability purposes under the Exchange Act. Akari also notes that the materials will only be incorporated into other securities law filings if specifically referenced in those future documents.
Akari Therapeutics, Plc reported a six-month net loss of $5.6 million and a cash and restricted cash balance of $2.7 million as of June 30, 2025. The company recorded an accumulated deficit of $252.9 million and explicitly stated that its cash balance is not sufficient to fund operations for the one-year period following issuance, which management says raises substantial doubt about the Company’s ability to continue as a going concern.
In November 2024 Akari completed the acquisition of Peak Bio, recording $39.18 million of in‑process R&D (IPR&D) and $8.43 million of goodwill tied to its ADC platform and payload PH1. During H1 2025 the company completed a March 2025 private placement with net proceeds of approximately $5.6 million and recognized a $1.2 million gain from settlement of payables. Shares outstanding increased to 65.23 billion ordinary shares at June 30, 2025, reflecting multiple financings and conversions. Subsequent events disclosed an August 2025 note purchase commitment for an aggregate purchase price of $3.0 million (aggregate principal issuable $3.8 million), expected to close in tranches.
Insider Trading Alert: Abizer Gaslightwala, President & CEO and Director of Akari Therapeutics, has increased his position through two separate purchases of American Depositary Shares (ADS):
- June 23, 2025: Acquired 943 ADS at $1.15 per share
- June 24, 2025: Acquired 5,203 ADS at weighted average price of $1.16
Following these transactions, Gaslightwala now directly owns 277,574 ADS. Each ADS represents 2,000 ordinary shares with $0.0001 par value. The insider's accumulation of shares at these price levels may signal management's confidence in the company's prospects. The Form 4 was filed within the required reporting timeframe and executed by Torsten Hombeck as Attorney-in-Fact.
Akari Therapeutics plc (NASDAQ: AKTX) – Form 4 insider transaction
On 06/20/2025, President & Chief Executive Officer Abizer Gaslightwala, who also serves as a director of the company, purchased 10,000 American Depositary Shares (ADS) of Akari Therapeutics in an open-market transaction. The shares were acquired at a price of $1.20 per ADS, for an aggregate consideration of approximately $12,000.
Following the purchase, the reporting person’s direct holding increased to 271,428 ADS. Each ADS represents 2,000 ordinary shares of Akari Therapeutics with a par value of $0.0001 per ordinary share, as noted in the footnote to the filing.
No dispositions were reported, and the filing shows no derivative security transactions. The form was signed by Torsten Hombeck, acting as attorney-in-fact, on 06/24/2025.
This Form 4 therefore documents a single, straightforward insider purchase by the company’s most senior executive, with no accompanying sales or option exercises disclosed.
Insider Purchase Alert: Abizer Gaslightwala, President & CEO and Director of Akari Therapeutics, has acquired 15,000 American Depositary Shares (ADS) at a price of $1.20 per share on June 17, 2025. Each ADS represents 2,000 ordinary shares of the company.
Following this transaction, Gaslightwala now beneficially owns 261,428 ADSs directly. This insider purchase demonstrates a significant investment by the company's top executive, potentially signaling confidence in the company's future prospects.
- Transaction Type: Direct Purchase (Form 4)
- Total Investment Value: $18,000
- Transaction Date: June 17, 2025
- Filing Date: June 28, 2025
- Ownership Form: Direct